{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:40Z","timestamp":1791216760591,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The ASTRUM-005 phase 3 randomized clinical trial showed substantial survival benefit from adding serplulimab to chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC). However, the long-term outcomes are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy, safety, patient-reported outcomes (PROs), and exploratory biomarker findings from ASTRUM-005 at an extended follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This international, double-blind, phase 3 randomized clinical trial enrolled patients from September 12, 2019, to April 27, 2021 in China, Russia, Ukraine, Poland, Turkey, and Georgia. Eligible patients had histologically or cytologically confirmed ES-SCLC with no prior systemic therapy. Patients were followed up through May 7, 2024, and the data analysis of this prespecified, secondary analysis lasted from August to September 2024. The median follow-up duration was 42.4 months (range, 0.2-55.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Patients were randomized in a 2:1 ratio to receive intravenous serplulimab (4.5 mg\/kg; serplulimab group) or placebo (placebo group), which was combined with up to 4 cycles of carboplatin and etoposide every 3 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>The primary end point was overall survival (OS). Secondary end points included other efficacy end points, safety, and PROs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 585 patients (median [range] age was 63 [28-76] years in the serplulimab group and 62 [31-83] years in the placebo group) with previously untreated ES-SCLC, and 389 (66.5%) were randomly assigned to the serplulimab group and 196 (33.5%) to the placebo group. Baseline characteristics were balanced across treatment groups. At data cutoff, 280 OS events (72.0%) in the serplulimab group and 166 (84.7%) in the placebo group were observed. Compared with the placebo group, the serplulimab group showed more favorable efficacy (median OS, 15.8 [95% CI, 13.9-17.4] vs 11.1 [95% CI, 10.0-12.4] months; hazard ratio, 0.60; 95% CI, 0.49-0.73;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The serplulimab group showed improved OS rates at 4 years compared with the placebo group (21.9% vs 7.2%). Grade 3 or higher serplulimab-related or placebo-related treatment-emergent adverse events occurred for 136 (35.0%) and 57 patients (29.1%) in the respective groups. A PRO analysis revealed consistent trends of improved overall health, dyspnea, and pain in both groups and faster recovery from alopecia in the serplulimab group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This secondary analysis of a randomized clinical trial demonstrated long-term benefit from adding serplulimab to chemotherapy for previously untreated patients with ES-SCLC, supporting this therapy as a first-line standard of care for this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04063163?term=NCT04063163&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT04063163<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1645","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:30:27Z","timestamp":1780587027000},"page":"810","source":"Crossref","is-referenced-by-count":4,"title":["First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Jingjing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Linyi Cancer Hospital, Linyi, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cangzhou People\u2019s Hospital, Cangzhou, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Provincial Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Anhui Chest Hospital, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksym","family":"Viguro","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Medical Center \u201cMriya Med-Service,\u201d Kryvyi Rih, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junquan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tangshan People\u2019s Hospital, Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamta","family":"Makharadze","sequence":"additional","affiliation":[{"name":"Department of Oncology-Endocrinology, High Technology Hospital MedCenter, Batumi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterine","family":"Arkania","sequence":"additional","affiliation":[{"name":"Department of Oncology, Israeli-Georgian Medical Research Clinic \u201cHelsicore,\u201d Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Global Product Development, Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Global Product Development, Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Innovation Center, Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Global Product Development, Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Chairperson of the Board Office, Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ASTRUM-005 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Zhong","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"T\u00fcrker","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Tavartkiladze","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiran","family":"Matitashvili","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Akopov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrii","family":"Gardashnikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Cao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davit","family":"Giorgadze","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denys","family":"Pominchuk","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"Cabuk","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongji","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeny","family":"Kulikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Moiseenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyan","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"An","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Sun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Feng","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Song","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Huang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Harputluoglu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Lifirenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sinelnikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Lu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Ying","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Penkov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Nie","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Lu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yue","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Gumus","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksym","family":"Viguro","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ulanska","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Smagina","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Zhvania","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fan","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ozguroglu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Kobziev","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii","family":"Kolesnik","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olexandr","family":"Goloborodko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Cao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mroz","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Cheporov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Orlov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenpeng","family":"Ying","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariel","family":"Kitiashvili","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Andabekov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsira","family":"Kortua","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"Goksel","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Shirinkin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimer","family":"Kuchava","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Zhuo","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Hu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevhen","family":"Hotko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Urun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Semegen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"You","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Lin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi260023r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi260023r2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer.","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"coi260023r5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"coi260023r6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"coi260023r7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial.","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"coi260023r8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi260023r9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial.","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi260023r10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial.","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"coi260023r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257972","article-title":"Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.","volume":"16","author":"Issafras","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"coi260023r12","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2419838","article-title":"Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies.","volume":"16","author":"Zhang","year":"2024","journal-title":"MAbs"},{"issue":"8","key":"coi260023r13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cac2.70032","article-title":"First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.","volume":"45","author":"Cheng","year":"2025","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"coi260023r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4830","article-title":"Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011-2018.","volume":"5","author":"Tseng","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"21","key":"coi260023r15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review.","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"4","key":"coi260023r16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.21037\/tlcr.2018.05.14","article-title":"Lung cancer in never smokers-the East Asian experience.","volume":"7","author":"Zhou","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"coi260023r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III Imbrella A extension study.","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"coi260023r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"coi260023r19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi260023r20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi260023r21","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/curroncol30040275","article-title":"Prevention and treatment of chemotherapy-induced alopecia: what is available and what is coming?","volume":"30","author":"Wikramanayake","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"coi260023r22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.36849\/JDD.7828","article-title":"Alopecia as an adverse event of immune checkpoint inhibitor therapies: clinical evidence and outcomes.","volume":"24","author":"Park","year":"2025","journal-title":"J Drugs Dermatol"},{"issue":"23","key":"coi260023r27","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1111\/1759-7714.14684","article-title":"Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.","volume":"13","author":"Yang","year":"2022","journal-title":"Thorac Cancer"},{"issue":"4","key":"coi260023r28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jjco\/hyae175","article-title":"Real-world treatment patterns and survival in extensive stage small-cell lung cancer in Japan.","volume":"55","author":"Horinouchi","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"coi260023r29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4143\/crt.2023.913","article-title":"The real-world outcome of first line atezolizumab in extensive-stage small cell lung cancer: a multicenter prospective cohort study.","volume":"56","author":"Choi","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"1","key":"coi260023r30","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1038\/s41598-020-63656-7","article-title":"Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women.","volume":"10","author":"Chen","year":"2020","journal-title":"Sci Rep"},{"key":"coi260023r31","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/OTT.S100949","article-title":"Association between cooking oil fume exposure and lung cancer among Chinese nonsmoking women: a meta-analysis.","volume":"9","author":"Xue","year":"2016","journal-title":"Onco Targets Ther"},{"key":"coi260023r3","unstructured":"American Cancer Society. Cancer facts & figures. Accessed December 26, 2025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf"},{"key":"coi260023r4","unstructured":"National Comprehensive Cancer Network. NCCN guidelines\u2013small cell lung cancer: version 4.2025. Accessed December 26, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf"},{"key":"coi260023r23","unstructured":"World Health Organization. Global Adult Tobacco Survey (GATS) fact sheet China: 2010. Accessed April 2, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/china\/gats\/en-tfi-china-gats-factsheet-2010.pdf?sfvrsn=df210d51_3&download=true"},{"key":"coi260023r24","unstructured":"World Health Organization. Global Adult Tobacco Survey (GATS) fact sheet Poland: 2009. Accessed April 2, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/poland\/poland-gats-2009-2010.pdf?sfvrsn=a834f88d_1&download=true"},{"key":"coi260023r25","unstructured":"World Health Organization. Global Adult Tobacco Survey (GATS) fact sheet Russian Federation: 2009. Accessed April 2, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/russian-federation\/gats_fs_rus_2009_eng.pdf?sfvrsn=1c363b4c_1&download=true"},{"key":"coi260023r26","unstructured":"World Health Organization. Global Adult Tobacco Survey (GATS) fact sheet Ukraine: 2010. Accessed April 2, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/ukraine\/ukraine-gats-2010-fact-sheet.pdf?sfvrsn=c0e033f4_1&download=true"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2849978\/jamaoncology_liu_2026_oi_260023_1790787085.86144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:08:08Z","timestamp":1790867288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2849978"}},"subtitle":["Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1645","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}